GeneDx Holdings (WGS) Receivables - Net (2020 - 2026)

GeneDx Holdings (WGS) has reported Receivables - Net for 7 consecutive years, with $83.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Net rose 74.09% year-over-year to $83.6 million in Q2 2026; TTM through Jun 2026 was $83.6 million, a 74.09% increase from a year earlier, with the FY2025 full-year figure at $74.4 million, up 97.64% from the prior year.
• Receivables - Net was $83.6 million for Q2 2026 at GeneDx Holdings, up from $76.9 million in the prior quarter.
• Over five years, Receivables - Net peaked at $83.6 million in Q2 2026 and troughed at $25.5 million in Q2 2024.
• A 5-year average of $45.4 million and a median of $40.4 million in 2022 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net soared 100.73% in 2022 and slipped 28.59% in 2023, its largest moves.
• Over 5 years, Receivables - Net stood at $42.6 million in 2022, then fell by 24.07% to $32.4 million in 2023, then advanced by 16.24% to $37.6 million in 2024, then soared by 97.64% to $74.4 million in 2025, then climbed by 12.42% to $83.6 million in 2026.
• The last three Receivables - Net figures came in at $83.6 million (Q2 2026), $76.9 million (Q1 2026), and $74.4 million (Q4 2025), per Business Quant data.